Fingerprint
Dive into the research topics of 'A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically